GlassScriptPhysician profile
Ronda Broady
NPI 1558381012
$2,831.65
in general payments reported to CMS, 2019-2025
24 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $149 · 2021: $14.27 · 2022: $108 · 2023: $994 · 2024: $517 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $775.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teladoc Health, INC. | $775.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $393.11 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $310.00 | 2022-2025 | Zepbound, Mounjaro, Amyvid |
| Teva Pharmaceuticals USA, INC. | $243.66 | 2024-2025 | Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $169.73 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.67 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $85.94 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $81.19 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $81.09 | 2019 | |
| Exact Sciences Corporation | $79.79 | 2024-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $79.67 | 2019-2022 | |
| Pfizer INC. | $68.46 | 2023-2025 | |
| Amarin Pharma, INC. | $64.54 | 2019 | |
| Seqirus USA INC | $45.97 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Alexion Pharmaceuticals, INC. | $36.64 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.01 | 2023-2025 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.77 | 2025 | Jardiance |
| Gilead Sciences, INC. | $23.73 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.21 | 2020 | |
| Boston Scientific Corporation | $20.00 | 2023 | Wavewriter Alpha Prime 16 |
| Linus Health, INC. | $17.69 | 2023 | |
| Genentech USA, INC. | $16.32 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.09 | 2019 | |
| Bausch Health US, LLC | $13.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronda Broady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.